HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

‘Strategic menu’ of noninvasive options needed to boost colorectal cancer screening rates

Editorial

Big data in bladder cancer: I call B.S.!

Derek Raghavan, MD, PhD

Supplement

New class of inhibitors change treatment paradigm in ALK-positive non-small cell lung cancer

Commentary

Progression of clinical exposure, understanding key to advanced practice provider onboarding

Janice Shipe-Spotloe, PA-C, MS, DFAAPA, CPAAPA

Practical considerations must guide combination treatment for older patients with advanced hormone receptor-positive breast cancer

Rachel A. Freedman, MD, MPH; Sara M. Tolaney, MD, MPH

Prognostication in myelofibrosis: Integrating genetics into routine practice

Gabriela Hobbs, MD

Imaging Analysis

Multimodality imaging of sinonasal undifferentiated carcinoma

Ana M. Franceschi, MD; Munir Ghesani, MD

Meeting News

Diverse gut microbiota may improve OS in allogeneic hematopoietic cell transplantation

Cancer centers lack aids to improve sexual dysfunction among survivors

Pembrolizumab induces durable responses in advanced liver cancer

Obese men at higher risk for recurrence after radical prostatectomy

Elotuzumab plus stem cell transplant shows promise for multiple myeloma

CAR T-cell therapy shows efficacy for extramedullary ALL

Novel drug shows early efficacy for steroid-dependent chronic GVHD

Ruxolitinib therapy appears safe prior to allogeneic HSCT for myelofibrosis

Data emerge on new immunotherapeutic targets for melanoma

Comprehensive follow-up care model stands to serve current, future HSCT survivors

CAR T-cell therapy may serve as bridge to transplantation for ALL

BRAF/MEK inhibitor therapy a preferred option for metastatic melanoma

Collaboration key to identification, incorporation of biomarkers for immuno-oncology

Real-world data can guide decisions about which patients should receive immunotherapy

High microsatellite instability, mutation load may predict checkpoint inhibitor response

CAR T-cell therapy holds promise for multiple myeloma

Survivorship role, responsibility needs a place in multidisciplinary cancer care team

Chlamydia infection may double risk for ovarian cancer

HER-2 mutations linked to hormone therapy resistance in breast cancer subtype

Providers less likely to recommend HPV vaccine to boys than girls

Participation in clinical trials may eliminate ovarian cancer survival disparities

PARP-7 mutation associated with longer ovarian cancer survival

Trend of patients acting like consumers will change cancer centers’ strategies

Incoming Association of Community Cancer Centers president to focus on cancer care team burnout ‘epidemic’

In the Journals Plus

High-deductible insurance plans linked to delays in breast cancer diagnosis, treatment

USPSTF endorses behavioral counseling to prevent skin cancer

Minimal residual disease more prognostic than remission in myeloma

Diffuse myocardial fibrosis may predict diastolic dysfunction in sickle cell anemia

Hydroxyurea linked to ‘significant, rapid’ reduction of sperm count

MRI-based prediction model may reduce unnecessary biopsies in prostate cancer

Savolitinib shows some activity for papillary renal cell carcinoma

Certain diets increase risk for colorectal cancer

Cardiovascular adverse events common with carfilzomib

Depressive symptoms may increase head, neck cancer mortality

Obese, overweight women at increased risk for cervical cancer

Insurers’ cost for chemotherapy varies across delivery location

FDA News

FDA approves Imfinzi for unresectable stage III NSCLC tumors

FDA grants breakthrough therapy designation to Promacta for severe aplastic anemia

FDA grants breakthrough therapy designation to erdafitinib for metastatic urothelial carcinoma

FDA grants priority review to frontline Darzalex for multiple myeloma

Moderate coffee intake reduces risk for liver cancer, cirrhosis, fibrosis

Transparent conversations needed across cancer continuum to improve patients’ illness understanding

Biosimilar PF-05280586 equivalent to rituximab for follicular lymphoma

Opdivo plus Yervoy improves PFS for non-small cell lung cancer with high tumor mutation burden

American Association for Cancer Research names president-elect

Prostate cancer expert named co-chair of NCI committee

Samuel Waxman Cancer Research Foundation to present award

Fox Chase Cancer Center oncologist to receive lifetime achievement award